The use of monotherapy in patients with epilepsy: An appraisal of the new antiepileptic drugs

被引：25

作者：

Kanner A.M. ^{[1
]}

Balabanov A.J. ^{[1
]}

机构：

[1] Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612

来源：

Current Neurology and Neuroscience Reports | 2005年 / 5卷 / 4期

关键词：

Gabapentin; Lamotrigine; Topiramate; Partial Seizure; Oxcarbazepine;

D O I：

10.1007/s11910-005-0078-0

中图分类号：

学科分类号：

摘要：

The use of antiepileptic drugs (AEDs) in monotherapy is always preferred to a polytherapy regimen because monotherapy facilitates drug compliance, is associated with a lower risk of toxicity, and is less costly. In addition, the yield of polytherapy to render a patient seizure-free when monotherapy regimens did not is relatively low. The available data derived from randomized controlled trials suggest that standard and new AEDs appear to display comparable antiepileptic efficacy but they differ with respect to tolerability and toxicity, which may be related to their pharmacodynamic and pharmacokinetic properties. New AEDs appear to be better tolerated than standard AEDs and to have fewer pharmacokinetic interactions than standard AEDs. In this article, we review the advantages of using AEDs in monotherapy in patients with newly diagnosed and refractory epilepsies, focusing on the individual properties of the drugs that may make them more appropriate in various patient groups. Copyright © 2005 by Current Science Inc.

引用

页码：322 / 328

页数：6

共 46 条

[1]

Weaver L.C., Swinyard E.A., Woodbury L.A., Goodman L.S., Studies on anticonvulsant drug combinations: Phenobarbital and diphenylhydantoin, J. Pharmacol. Exp. Ther., 113, pp. 359-370, (1955)

[2]

Leppik I.E., Sherwin A.L., Anticonvulsant activity of phenobarbital and phenytoin in combination, J. Pharmacol. Exp. Ther., 200, pp. 570-576, (1977)

[3]

Mattson R.H., Cramer J.A., Collins J.F., Et al., Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-donic seizures, N. Engl. J. Med., 313, pp. 145-151, (1985)

[4]

Gilliam F., Kuzniecky P., Faught E., Et al., Patient-validated content of epilepsy-specific quality-of-life measurement, Epilepsia, 38, pp. 233-236, (1997)

[5]

Mattson R.H., Cramer J.A., Collins J.F., A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults, N. Engl. J. Med., 327, pp. 765-771, (1992)

[6]

Heller A.J., Chesterman P., Elwes R.D., Et al., Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: A randomised comparative monotherapy trial, J. Neurol. Neurosurg. Psychiatry, 58, pp. 44-50, (1995)

[7]

Shimada T., Yamazaki H., Mimura M., Et al., Interindividual variation in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with the microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther., 270, pp. 414-423, (1994)

[8]

Pelkonen O., Maenpaa J., Taavitsainen P., Et al., Inhibition and induction of human cytochrome P450 (CYP) enzymes, Xenobiotica, 28, pp. 1203-1253, (1998)

[9]

Relling M.V., Pui C., Sandlund J., Et al., Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia, Lancet, 356, pp. 285-290, (2000)

[10]

Villikka K., Kivisto K.T., Maenpaa M.D., Et al., Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors, Clin. Pharm. Ther., 66, pp. 589-593, (1999)

← 1 2 3 4 5 →